Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0XPGYS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-HER3/Muc1 bsAb |
|||||
| Antigen Name | HER3; Muc1 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
DM002 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients (≥18 years, ECOG 0-2, life expectancy ≥3 months) must have measurable disease (RECIST 1.1), adequate organ function
|
||||
| Administration Dosage |
An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06751329 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Safety assessment includes DLT evaluation (grade 3 neurological/grade 4 toxicities) and MTD determination (0/3 or 1/6 DLT rate) for DM002 over 12 months.
|
||||
| Other Endpoint |
PK parameters (AUC, Cmax, Tmax, Ctrough) and efficacy (ORR per RECIST 1.1) will be analyzed for 12 months.
|
||||